Contrast agent production localised in Korea:
This article was originally published in Clinica
Ilsung Pharma of Korea has launched its own version of the non-ionic contrast agent, Ioparimo (iopamidol), under an arrangement with Bracco of Italy. Ilsung has distributed Bracco's product on the Korean market since 1984, but now plans to produce seven different formulations in its own factory with technical assistance from the Italian company, reports Pharma Koreana.
You may also be interested in...
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.
By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.